Ignite Creation Date:
2025-12-17 @ 4:27 PM
Ignite Modification Date:
2025-12-24 @ 1:32 AM
Study NCT ID:
NCT00722358
Status:
COMPLETED
Last Update Posted:
2011-06-27
First Post:
2008-07-23
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: